Related Experiment Video
Updated: Jun 29, 2025
Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines
Published on: October 8, 2015
BRAF/MEK-targeted therapy in BRAF ex15 p.T599dup mutation-driven NSCLC: a case report
Lan Jiang1, Pirong Yang1, Yufeng Liu1
1Medical Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Centre, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, 610041, China.
Abstract:
BRAF mutations are found in 1-5% of non-small-cell lung cancer (NSCLC), with V600 and non-V600 accounting for approximately 50% each. It has been confirmed that targeted therapy with dabrafenib + trametinib is effective in patients with metastatic NSCLC carrying BRAF V600E mutations. Preclinical studies have shown that dabrafenib + trametinib may also have inhibitory effects on some types of non-V600E mutations, especially some class II BRAF mutations. However, the efficacy of dabrafenib + trametinib on non-V600E mutant NSCLC in clinical practice only exists in some case reports. Here, we report a case of NSCLC patient carrying BRAF ex15 p.T599dup, who showed a clinical response to the combined therapy of dabrafenib + trametinib.
Insights
Targeted therapy with dabrafenib plus trametinib shows promise for non-small cell lung cancer (NSCLC) patients with rare BRAF non-V600E mutations. This case report highlights a positive response in a patient with a BRAF ex15 p.T599dup mutation.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- BRAF mutations occur in 1-5% of non-small cell lung cancer (NSCLC).
- BRAF V600E mutations are treatable with dabrafenib + trametinib.
- Non-V600E BRAF mutations are diverse, with limited clinical data on targeted therapies.
Observation:
- This study reports on a non-small cell lung cancer patient with a specific BRAF ex15 p.T599dup mutation.
- The patient received combined therapy with dabrafenib and trametinib.
Findings:
- The patient with BRAF ex15 p.T599dup NSCLC demonstrated a clinical response to dabrafenib + trametinib therapy.
- Preclinical data suggested potential efficacy of this combination for certain non-V600E mutations, including Class II variants.
Implications:
- This case suggests dabrafenib + trametinib may be effective for NSCLC with BRAF non-V600E mutations, specifically p.T599dup.
- Further clinical investigation is warranted to confirm the efficacy of this targeted therapy in a broader NSCLC population with non-V600E BRAF alterations.
More Related Videos
08:18Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma
Published on: September 8, 2021
06:09Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
Published on: June 7, 2019
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:23Abnormal Proliferation